Emerging from a round of private-equity fundraising that netted $8.2 million, NimbleGen officials said this week that they plan to direct the new funding to solidify production capacity for existing applications, expand customer service, build software analysis capabilities, and invest in new technologies.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.